Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

NCT06692270 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

Esophagus Cancer

Interventions

DRUG: Tislelizumab

Sponsor

Fujian Cancer Hospital